

Express Mail No.: EV231271220US
Date of Deposit: July 14, 2003

07-15-03

Attorney Docket No. 18242-511 (VI-0008-P3)

1617

TECH CENTER 1600/2900
JUL 17 2003

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Ackerman et al.
SERIAL NO.: 10/036,768 EXAMINER: Jennifer M. Kim
FILING DATE: November 6, 2001 ART UNIT: 1617
FOR: METHODS AND REAGENTS FOR EXTRACORPOREAL
IMMUNOMODULATORY THERAPY

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Response to June 13, 2003 Restriction Requirement (1 pg.);
2. Return Postcard.

Applicants believe that no fees are due in connection with this submission. However, the Commissioner is authorized to credit any overpayment or charge any deficiencies to Deposit Account No. 50-0311, Reference No. 18242-511 (VI-0008-P3). A duplicate copy of this Transmittal Letter is enclosed.

If the enclosed papers are considered incomplete, the Mail Room is respectfully requested to contact the undersigned collect at (617) 542-6000, Boston, Massachusetts.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 48,593
Ivor R. Elrifi, Reg. No. 39,529
David E. Johnson, Reg. No. 41,874
David E. Johnson, Reg. No. 41,874

Attorneys for Applicants
c/o MINTZ LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel.: (617) 542-6000
Fax: (617) 542-2241

Dated: July 14, 2003



30623

PATENT TRADEMARK OFFICE



Express Mail No.: EV231271220US
Date of Deposit: July 14, 2003

Attorney Docket No. 18242-511 (VI-0008-P3)

#12
7/14/03
RECEIVED
JUL
TECH CEN

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Ackerman et al.
SERIAL NO.: 10/036,768 EXAMINER: Jennifer M. Kim
FILING DATE: November 6, 2001 ART UNIT: 1617
FOR: METHODS AND REAGENTS FOR EXTRACORPOREAL
IMMUNOMODULATORY THERAPY


Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO REQUIREMENT FOR RESTRICTION

In response to the June 13, 2003 Office Action imposing a requirement for restriction, applicants elect Group I, which contains Claims 1-32, drawn to a method for treating a patient having an immune dysfunction comprising treating peripheral blood mononuclear cells with an aziridino-containing compound, classified in class 514, subclass 183. Applicants also elect species III, drawn to an active agent of formulae II-III (heterocyclic), without traverse. Claims 1-7, 9-20, and 22-32 read on the elected species.

The Commissioner is hereby authorized to charge payment of any additional fees required in connection with the paper(s) transmitted herewith, or to credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 18242-511 (VI-0008-P3).

Respectfully submitted,


Ivor R. Elrifi, Reg. No. 39,529
Attorney for Applicants
c/o MINTZ LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel.: (617) 542-6000
Fax: (617) 542-2241

Dated: July 14, 2003